Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomised, Placebo-controlled Phase I Trial to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Topical Doses of GZ21T in Healthy Volunteers

NCT06888362 is registered in ClinicalTrials.gov with Genzada Pharmaceuticals USA, Inc. as lead sponsor.

NCT NCT06888362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06888362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomised, Placebo-controlled Phase I Trial to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Topical Doses of GZ21T in Healthy Volunteers
Lead sponsor
Genzada Pharmaceuticals USA, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 19, 2024
Completion date
March 31, 2025
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis